Navigation Links
NASDAQ Grants China Jo-Jo Drugstores 180-Day Extension to Regain Compliance with Bid Price Requirement
Date:11/12/2013

HANGZHOU, China, Nov. 12, 2013 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (the "Company"), a retail and wholesale distributor of pharmaceutical and other healthcare products in China, today announced that on November 6, 2013, it received notification from NASDAQ granting the Company an additional 180-day period, or until May 5, 2014, to remain listed on the NASDAQ Capital Market and to regain compliance with NASDAQ's minimum $1.00 bid price per share rule.

Under NASDAQ Listing Rules, the Company was granted this extension because it met the continued listing requirement for market value of publicly held shares and all other applicable NASDAQ listing requirements, except the bid price requirement. The Company provided written notice to NASDAQ of its intention to cure the bid price deficiency during the second compliance period by affecting a reverse stock split, if necessary.

The Company will regain compliance with the minimum bid requirement if at any time prior to May 5, 2014, the bid price for the Company's common stock closes at $1.00 per share or above for a minimum of 10 consecutive business days.

If the Company does not regain compliance by the end of this extension period, it will receive notification from NASDAQ that its shares are subject to delisting. At that point, the Company may then appeal the delisting determination to a NASDAQ Hearings Panel.

About China Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc., through its subsidiaries and contractually controlled affiliates, is a retailer and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. As of September 30, 2013, the Company had 51 retail pharmacies throughout Zhejiang Province and Shanghai.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.


'/>"/>
SOURCE China Jo-Jo Drugstores, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
2. Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
3. Hologic to Mark Start of Breast Cancer Awareness Month with NASDAQ Opening Bell Ceremony
4. Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform
5. Cyberonics Reports Inducement Equity Award Under NASDAQ Listing Rule 5635(c)(4)
6. VirtualScopics Regains NASDAQ Compliance
7. Henry Schein to Open NASDAQ Stock Market to Celebrate Rebranding of U.S. Animal Health Business
8. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Anthera Pharmaceuticals Announces Receipt of Nasdaq Notice
10. Ohr Pharmaceutical Announces Approval for Listing on NASDAQ
11. The Law Offices of Marc S. Henzel Announces Class Action Lawsuit Against Aveo Pharmaceuticals, Inc. and Certain Officers -- (Nasdaq: AVEO) was filed on behalf of stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials ... combine to progress molecular radiotherapy imaging. In molecular ... to accurately quantify the radiation absorbed by those patients undergoing ... of this radiotherapy treatment has been available — that is, ... ...
(Date:7/5/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade cell and tissue hypothermic storage ... that it has reached an agreement with WAVI Holding ... modify its existing credit facility effective June 30, 2017. ... to exchange its existing $4.25 million credit facility, including ...
(Date:6/30/2017)... (AVACEN) announced the publication of new research in the peer-reviewed Fibromyalgia ... AVACEN Treatment Method to significantly reduce the widespread pain symptom ... ... ... to 400 million people worldwide according to The National Fibromyalgia Association. ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... selected to renovate and improve the Ramsey County Medical Examiners Facility located in ... Hospital, the $2.5 million project is scheduled to start in late 2017/early 2018. ...
(Date:7/21/2017)... ... 21, 2017 , ... Bernard R. Bach, Jr., MD, orthopaedic surgeon at Rush ... Society of Sports Medicine (AOSSM) , received the 2017 Robert E. Leach Sports Medicine ... Canada. This prestigious award is given annually to honor those who have made a ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... 4th-year medical students improve their chances of acceptance to a residency in a ... who have earned degrees outside the U.S. , According to data released by ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... with over 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome ... knee-related quality of life a decade after surgery, though activity levels decline over ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ChenMed ... MD, has joined JenCare Senior Medical Center as Richmond Chief Medical Officer. ... School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA ...
Breaking Medicine News(10 mins):